Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Background: Peripheral T-cell lymphomas (PTCLs), rare heterogeneous aggressive non-Hodgkin lymphoma (NHL) subtypes, generally have poor outcomes for all patient age groups. Few data are available on the clinical features and treatment outcomes for older adults with PTCLs. Given this gap in the liter...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144, p.6402-6402
Main Authors: Skrypets, Tetiana, Alpdogan, Onder, Conte, Luana, Civallero, Monica, Lymboussaki, Athina, Vose, Julie M., Dlouhy, Ivan, Cabrera, Maria Elena, Hitz, Felicitas, Bobillo, Sabela, Kim, Won Seog, Nagler, Arnon, Marino, Dario, Advani, Ranjana H., Stelitano, Caterina, Porcu, Pierluigi, Federico, Massimo
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Peripheral T-cell lymphomas (PTCLs), rare heterogeneous aggressive non-Hodgkin lymphoma (NHL) subtypes, generally have poor outcomes for all patient age groups. Few data are available on the clinical features and treatment outcomes for older adults with PTCLs. Given this gap in the literature, the purpose of this sub-analysis was to assess the clinical information, therapeutic approaches, and outcome of patients (>65 years old) included in the T-Cell Project 1.0 (clinicaltrials.gov: 01142674) and to investigate potential prognostic factors. Methods: The TCP 1.0 is a prospective international registry that collected clinical data and biological information of 1553 cases with PTCL at 75 institutions worldwide between 2006-2018. We identified 566 patients aged 65+. Baseline patient characteristics have been summarized with descriptive statistics. Survival analyses were performed using Kaplan-Meier method. Results: The median age of patients >65 years old was 72 years (range 65-90) with a slight male predominance (56.4%). The majority had ECOG 0-1 (65.8 %) and advanced stage III/IV (62%), and 44.5% of cases had extranodal involvement. The most frequent histological subtypes were PTCL NOS (236 cases, 41.7%), AITL (159, 28.1%), and ALCL ALK neg (69, 12.2%). The median follow-up for living patients was 36 months (2-139 months). Five year overall survival (OS) and progression-free survival (PFS) were 31% and 14%, respectively. B symptoms (p
ISSN:0006-4971
DOI:10.1182/blood-2024-203976